JP2015529641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529641A5 JP2015529641A5 JP2015521849A JP2015521849A JP2015529641A5 JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5 JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- tumor
- variable region
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 102000015735 Beta-catenin Human genes 0.000 claims description 6
- 108060000903 Beta-catenin Proteins 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 claims description 5
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000054144 human RSPO3 Human genes 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029640 digestive system melanoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 2
- 101150116752 Rspo3 gene Proteins 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 description 1
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671421P | 2012-07-13 | 2012-07-13 | |
| US61/671,421 | 2012-07-13 | ||
| US201361753184P | 2013-01-16 | 2013-01-16 | |
| US61/753,184 | 2013-01-16 | ||
| US201361789156P | 2013-03-15 | 2013-03-15 | |
| US61/789,156 | 2013-03-15 | ||
| US201361826747P | 2013-05-23 | 2013-05-23 | |
| US61/826,747 | 2013-05-23 | ||
| PCT/US2013/050300 WO2014012007A2 (en) | 2012-07-13 | 2013-07-12 | Rspo3 binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529641A JP2015529641A (ja) | 2015-10-08 |
| JP2015529641A5 true JP2015529641A5 (enExample) | 2016-09-01 |
| JP6335896B2 JP6335896B2 (ja) | 2018-05-30 |
Family
ID=49914164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521849A Expired - Fee Related JP6335896B2 (ja) | 2012-07-13 | 2013-07-12 | Ｒｓｐｏ３結合剤およびその使用法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9181333B2 (enExample) |
| EP (1) | EP2872175A4 (enExample) |
| JP (1) | JP6335896B2 (enExample) |
| KR (1) | KR20150036603A (enExample) |
| CN (1) | CN104854132A (enExample) |
| AU (1) | AU2013289990B2 (enExample) |
| BR (1) | BR112015000776A2 (enExample) |
| CA (1) | CA2878868A1 (enExample) |
| CL (1) | CL2015000097A1 (enExample) |
| EA (1) | EA032038B1 (enExample) |
| EC (1) | ECSP15005280A (enExample) |
| HK (1) | HK1208687A1 (enExample) |
| IL (1) | IL236617A0 (enExample) |
| IN (1) | IN2015KN00350A (enExample) |
| MX (1) | MX2015000565A (enExample) |
| NI (1) | NI201500002A (enExample) |
| NZ (1) | NZ704269A (enExample) |
| PE (1) | PE20150360A1 (enExample) |
| PH (1) | PH12015500084A1 (enExample) |
| SG (1) | SG11201500233PA (enExample) |
| TW (2) | TW201906861A (enExample) |
| UA (1) | UA117659C2 (enExample) |
| WO (1) | WO2014012007A2 (enExample) |
| ZA (1) | ZA201500872B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP3009148B1 (en) | 2007-07-02 | 2018-08-22 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| AU2012271413B2 (en) | 2011-06-17 | 2017-07-13 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
| EP3401329A1 (en) | 2011-07-15 | 2018-11-14 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| JP6335896B2 (ja) | 2012-07-13 | 2018-05-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ３結合剤およびその使用法 |
| CN105744954B (zh) * | 2013-10-18 | 2021-03-05 | 豪夫迈·罗氏有限公司 | 抗rspo2和/或抗rspo3抗体及其用途 |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| CA2961374A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN106913880B (zh) * | 2015-12-24 | 2021-02-12 | 上海交通大学 | 一种含有rspo1的靶向给药系统及其制备与应用 |
| CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
| EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
| WO2018035210A1 (en) * | 2016-08-17 | 2018-02-22 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with an rspo antagonist |
| JP7370997B2 (ja) | 2017-12-07 | 2023-10-30 | ナショナル ヘルス リサーチ インスティテューツ | 抗ｒｓｐｏ３抗体 |
| CN110339364B (zh) * | 2018-04-02 | 2021-02-12 | 上海邦耀生物科技有限公司 | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 |
| CN110467663B (zh) * | 2019-06-18 | 2022-05-10 | 华南农业大学 | Rspo3基因在母猪卵巢颗粒细胞中的应用 |
| US20250346890A1 (en) * | 2019-12-19 | 2025-11-13 | Deutsches Krebsforschungszentrum | Leukemia treatment |
| KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
| CN116769030B (zh) * | 2023-08-21 | 2023-10-20 | 成都大熊猫繁育研究基地 | 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
| JP2001527403A (ja) | 1997-04-25 | 2001-12-25 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| WO1999015660A1 (en) | 1997-09-24 | 1999-04-01 | Merck & Co., Inc. | G-protein coupled glycoprotein hormone receptor hg38 |
| US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| DE69941330D1 (de) | 1998-03-26 | 2009-10-08 | Univ R | Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
| WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
| EP1572987A4 (en) | 2000-02-03 | 2005-11-30 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
| US6924141B2 (en) | 2000-03-31 | 2005-08-02 | The General Hospital Corporation | Methods of modulating hair growth |
| CA2405104A1 (en) | 2000-04-05 | 2001-10-18 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001281791A1 (en) | 2000-05-30 | 2001-12-11 | Bayer Aktiengesellschaft | Regulation of human lgr4-like g protein-coupled receptor |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US20050089518A1 (en) | 2001-12-07 | 2005-04-28 | Clarke Michael F. | Prospective identification and characterization of breast cancer stem cells |
| US6768004B2 (en) | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
| US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
| US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| WO2002100898A2 (en) | 2001-06-11 | 2002-12-19 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| ATE553193T1 (de) | 2001-08-30 | 2012-04-15 | Arca Biopharma Inc | Verfahren und materialien in verbindung mit stammzellen-wachstumsfaktor-ähnlichen polypeptiden und polynukleotiden |
| CA2462795A1 (en) | 2001-10-03 | 2003-04-10 | Incyte Genomics, Inc. | Secreted proteins |
| US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| CA2469941A1 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US7439332B2 (en) | 2002-04-26 | 2008-10-21 | Kirin Pharma Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004074436A2 (en) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
| US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
| EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005110009A2 (en) | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
| DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| EP1673475B1 (en) | 2003-10-10 | 2010-04-28 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
| WO2005040828A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
| JP2007526248A (ja) | 2004-01-27 | 2007-09-13 | ヌベロ インコーポレーティッド | 胃腸増殖因子およびその使用方法 |
| WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| US7572456B2 (en) | 2004-09-13 | 2009-08-11 | Macrogenics, Inc. | Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| WO2006110585A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
| EP1917022A2 (en) | 2005-07-26 | 2008-05-07 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
| US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
| EP1942926A4 (en) | 2005-10-07 | 2010-06-16 | Nuvelo Inc | STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES |
| US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| ES2378097T3 (es) | 2006-06-02 | 2012-04-04 | Aveo Pharmaceuticals, Inc. | ProteÃnas de unión al factor de crecimiento de hepatocitos (HGF) |
| ATE495195T1 (de) | 2006-06-02 | 2011-01-15 | Aveo Pharmaceuticals Inc | Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| NZ574215A (en) * | 2006-07-18 | 2012-07-27 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| DK2081586T4 (en) | 2006-10-20 | 2019-01-21 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Rspondins as modulators of angiogenesis and vasculogenesis |
| WO2008075796A1 (ja) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
| WO2008088524A2 (en) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
| EP2164871A2 (en) | 2007-06-12 | 2010-03-24 | Wyeth a Corporation of the State of Delaware | Anti-cd20 therapeutic compositions and methods |
| EP3009148B1 (en) | 2007-07-02 | 2018-08-22 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| US20100285001A1 (en) | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
| WO2009063970A1 (ja) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | 抗gpr49抗体を用いる癌の診断および治療 |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| KR101682257B1 (ko) * | 2008-10-31 | 2016-12-05 | 도레이 카부시키가이샤 | 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법 |
| US20120039912A1 (en) | 2009-04-15 | 2012-02-16 | Galapagos Sasu | Rspondin-3 inhibition in bone disorders |
| WO2010129284A1 (en) | 2009-04-27 | 2010-11-11 | The Trustees Of The University Of Pennsylvania | Inhibition of hair follicle growth by the wnt inhibitor dkk1 |
| CN102459346B (zh) * | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| CN102695499A (zh) | 2009-06-18 | 2012-09-26 | 惠氏有限责任公司 | 小模块免疫药物的冻干制剂 |
| US8318162B2 (en) * | 2009-07-16 | 2012-11-27 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| WO2011076932A1 (en) | 2009-12-23 | 2011-06-30 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
| WO2011085289A1 (en) | 2010-01-11 | 2011-07-14 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Production of a monoclonal antibody therapeutic against west nile virus in plants |
| NZ601743A (en) | 2010-02-12 | 2014-11-28 | Oncomed Pharm Inc | Methods for identifying and isolating cells expressing a polypeptide |
| US20150024952A1 (en) * | 2010-12-28 | 2015-01-22 | Arlet Alarcon | Molecular profiling for cancer |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| AU2012248158C1 (en) * | 2011-04-28 | 2017-02-02 | Sbi Biotech Co., Ltd. | Anti-human receptor-type protein tyrosine phosphatase sigma antibody |
| EP3401329A1 (en) | 2011-07-15 | 2018-11-14 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
| US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
| US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
| MX366804B (es) | 2012-02-11 | 2019-07-25 | Genentech Inc | Translocaciones de la r-espondina y sus metodos de uso. |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| JP6335896B2 (ja) | 2012-07-13 | 2018-05-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ３結合剤およびその使用法 |
| CN105142641A (zh) | 2013-03-12 | 2015-12-09 | 广州源生医药科技有限公司 | 用于治疗癌症的化合物 |
| JPWO2014192974A1 (ja) | 2013-05-30 | 2017-02-23 | 株式会社オーダーメードメディカルリサーチ | 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬 |
| CN105744954B (zh) | 2013-10-18 | 2021-03-05 | 豪夫迈·罗氏有限公司 | 抗rspo2和/或抗rspo3抗体及其用途 |
| MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
-
2013
- 2013-07-12 JP JP2015521849A patent/JP6335896B2/ja not_active Expired - Fee Related
- 2013-07-12 CA CA2878868A patent/CA2878868A1/en not_active Abandoned
- 2013-07-12 PE PE2015000037A patent/PE20150360A1/es active IP Right Grant
- 2013-07-12 KR KR1020157003862A patent/KR20150036603A/ko not_active Ceased
- 2013-07-12 MX MX2015000565A patent/MX2015000565A/es unknown
- 2013-07-12 US US13/940,834 patent/US9181333B2/en not_active Expired - Fee Related
- 2013-07-12 CN CN201380047332.9A patent/CN104854132A/zh active Pending
- 2013-07-12 HK HK15109369.7A patent/HK1208687A1/xx unknown
- 2013-07-12 EP EP13816428.0A patent/EP2872175A4/en not_active Withdrawn
- 2013-07-12 BR BR112015000776A patent/BR112015000776A2/pt not_active Application Discontinuation
- 2013-07-12 SG SG11201500233PA patent/SG11201500233PA/en unknown
- 2013-07-12 EA EA201590144A patent/EA032038B1/ru not_active IP Right Cessation
- 2013-07-12 WO PCT/US2013/050300 patent/WO2014012007A2/en not_active Ceased
- 2013-07-12 AU AU2013289990A patent/AU2013289990B2/en not_active Ceased
- 2013-07-12 IN IN350KON2015 patent/IN2015KN00350A/en unknown
- 2013-07-12 NZ NZ704269A patent/NZ704269A/en not_active IP Right Cessation
- 2013-07-15 TW TW107121349A patent/TW201906861A/zh unknown
- 2013-07-15 TW TW102125212A patent/TWI636061B/zh not_active IP Right Cessation
- 2013-12-07 UA UAA201500865A patent/UA117659C2/uk unknown
-
2015
- 2015-01-11 IL IL236617A patent/IL236617A0/en unknown
- 2015-01-12 NI NI201500002A patent/NI201500002A/es unknown
- 2015-01-13 CL CL2015000097A patent/CL2015000097A1/es unknown
- 2015-01-13 PH PH12015500084A patent/PH12015500084A1/en unknown
- 2015-02-06 ZA ZA2015/00872A patent/ZA201500872B/en unknown
- 2015-02-12 EC ECIEPI20155280A patent/ECSP15005280A/es unknown
- 2015-09-30 US US14/870,145 patent/US9598497B2/en active Active
-
2017
- 2017-02-22 US US15/439,288 patent/US20170267776A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529641A5 (enExample) | ||
| JP2014524746A5 (enExample) | ||
| JP6872537B2 (ja) | 抗ｌａｇ３抗体およびその使用 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| AU2015240599B2 (en) | Humanized antibodies that bind LGR5 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2011115117A (ru) | Нацеленные средства связывания, направленные на dll4, и их применение | |
| JP2016187356A5 (enExample) | ||
| JP2010518820A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2010532169A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2016128474A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2014527814A5 (enExample) | ||
| JP2012501626A5 (enExample) | ||
| JP2012523848A5 (enExample) | ||
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| JP2015506912A5 (enExample) | ||
| CN109311978B (zh) | Dsg2单克隆抗体和其用途 | |
| JP2012525149A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |